STAND (Shortening Treatment by Advancing Novel Drugs) Trial
Source: View publication →
The STAND Phase 3 trial evaluated the safety and efficacy of pretomanid, moxifloxacin, and pyrazinamide (PaMZ) regimens for drug-susceptible and drug-resistant tuberculosis, but recruitment was halted prematurely after enrolling only 284 patients, limiting the study's ability to draw definitive conclusions on non-inferiority.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STAND trial highlights the challenges of clinical development in tuberculosis, specifically the difficulty in balancing shorter treatment durations with safety and efficacy. While the PaMZ regimen was an early candidate for shortening treatment, the trial serves as a cautionary tale on the importance of robust safety monitoring and the potential for better-performing regimens (like BPaMZ) to supersede early experimental drug combinations.
Historical Context
For over 40 years, the standard treatment for drug-susceptible tuberculosis has been a 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol. The STAND trial, initiated in 2015, aimed to introduce a revolutionary 4-month or 6-month regimen using the novel drug pretomanid combined with moxifloxacin and pyrazinamide, but the project was reprioritized to more promising subsequent regimens after the clinical hold.
Guided Discussion
High-yield insights from every perspective
The STAND trial evaluated the PaMZ regimen, which includes the novel drug pretomanid. What are the two distinct mechanisms of action by which pretomanid kills Mycobacterium tuberculosis in both aerobic and anaerobic conditions?
Key Response
Pretomanid is a nitroimidazole that inhibits mycolic acid biosynthesis (blocking cell wall synthesis) in actively replicating aerobic bacteria and acts as a respiratory poison through the release of reactive nitrogen species (like nitric oxide) in non-replicating anaerobic bacteria. This dual action is foundational for its potential to clear 'persisters' and shorten therapy.
A patient with drug-susceptible TB is interested in a 4-month treatment regimen. Based on the outcomes of the STAND trial compared to the more successful Study 31/A5349, why is the PaMZ regimen not currently the preferred choice for treatment shortening in clinical practice?
Key Response
The STAND trial was terminated prematurely and failed to provide definitive Phase 3 evidence of non-inferiority for the PaMZ regimen. In contrast, Study 31/A5349 successfully demonstrated that a 4-month regimen of Rifapentine, Moxifloxacin, Isoniazid, and Pyrazinamide was non-inferior to the standard 6-month RIPE regimen, making the latter the evidence-based standard for treatment shortening.
Considering the moxifloxacin component in the PaMZ regimen studied in STAND, how does baseline fluoroquinolone resistance in a community affect the generalizability and safety of implementing this regimen for drug-susceptible TB?
Key Response
If a patient has undiagnosed baseline resistance to moxifloxacin, the PaMZ regimen essentially becomes dual therapy (Pretomanid and Pyrazinamide), significantly increasing the risk of selecting for further resistance (especially to pretomanid) and increasing the likelihood of treatment failure or relapse, as the 'backbone' of the regimen is compromised.
The STAND trial faced significant recruitment challenges that led to its early termination. In the context of global TB drug development, what does this trial's failure to complete signify for the feasibility of using 'universal regimens' for both DS-TB and DR-TB?
Key Response
The STAND trial's struggle highlights the difficulty of enrolling DS-TB patients in trials for experimental regimens when a highly effective standard of care (RIPE) already exists. It suggests that while 'universal regimens' are scientifically attractive to simplify programs, the bar for safety and efficacy in DS-TB is exceptionally high, and any signal of toxicity (like the hepatotoxicity seen in earlier PaMZ phases) can stall progress.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STAND trial reported results despite a significantly underpowered sample size. What are the primary statistical hazards of interpreting 'point estimates' for treatment success in early-terminated non-inferiority trials, and how should researchers handle 'imprecision' in these datasets?
Key Response
In underpowered non-inferiority trials, the confidence intervals (CIs) are typically too wide to exclude the non-inferiority margin. Even if the point estimate looks favorable, the imprecision means the 'null hypothesis' of inferiority cannot be rejected. Researchers must emphasize the width of the CIs and avoid concluding efficacy based on descriptive statistics alone, treating the data as hypothesis-generating rather than confirmatory.
When reviewing a manuscript for a trial like STAND that stopped early due to 'slow accrual' rather than 'futility' or 'harm,' what specific ethical and validity concerns must be addressed regarding the risk of overestimating treatment effects?
Key Response
Editors must look for 'stopping bias,' where trials that stop early may represent a random high in the data. Furthermore, the editor must ensure the authors don't conflate 'lack of evidence of a difference' with 'evidence of no difference.' The manuscript must be scrutinized for whether the ethics of exposing 284 patients to an experimental regimen were justified if the study was ultimately unable to answer its primary scientific question.
Currently, WHO and ATS/CDC/IDSA guidelines recommend the 4-month Rifapentine-Moxifloxacin regimen for DS-TB. Why does the STAND trial data fail to support the inclusion of PaMZ as an alternative 4-month recommendation in these guidelines?
Key Response
Per the GRADE framework, the 'certainty of evidence' from the STAND trial is very low due to extreme imprecision (imminent risk of Type II error). Existing guidelines require high-certainty Phase 3 evidence for a paradigm shift. Because STAND did not reach its accrual target, it cannot provide the robust evidence of non-inferiority required to move PaMZ into the standard-of-care recommendations alongside the Rifapentine-Moxifloxacin regimen supported by the A5349 trial.
Clinical Landscape
Noteworthy Related Trials
REMoxTB Trial
Tested
Moxifloxacin-containing 4-month regimens
Population
Patients with smear-positive pulmonary tuberculosis
Comparator
Standard 6-month regimen
Endpoint
Status at 18 months post-randomization
RIFHOPE Trial
Tested
Rifapentine-based 4-month regimen
Population
Patients with drug-susceptible pulmonary tuberculosis
Comparator
Standard 6-month regimen
Endpoint
Treatment outcome at 12 months
TBTC Study 31/A5349
Tested
Rifapentine and moxifloxacin-based 4-month regimen
Population
Patients with drug-susceptible pulmonary tuberculosis
Comparator
Standard 6-month regimen
Endpoint
TB disease-free survival at 12 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis